|
rs10046
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A common haplotype composed of the Val(80) G allele and three haplotype-tagging single nucleotide polymorphisms (rs727479, rs10046, and rs4646) in the CYP19 coding region showed a trend to association with breast cancer risk in BRCA1 carriers ages <50 years.
|
19366906 |
2009 |
|
rs4646
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A common haplotype composed of the Val(80) G allele and three haplotype-tagging single nucleotide polymorphisms (rs727479, rs10046, and rs4646) in the CYP19 coding region showed a trend to association with breast cancer risk in BRCA1 carriers ages <50 years.
|
19366906 |
2009 |
|
rs700519
|
|
|
0.070 |
GeneticVariation |
BEFREE |
A DNA bank of patients with gynecologic oncology, patients with breast cancer (n = 335), and healthy women (n = 530) was created, and the following single-nucleotide polymorphisms were examined: CYP1A1 M1 polymorphism, that is, T264-C transition in the 30-noncoding region; CYP1A2*1F polymorphism, that is, C734-A transversion in the CYP1A2 gene; C-T transition (Arg264Cys) in exon 7 of CYP19; and SULT1A1*2 polymorphism, that is, G638-A transition (Arg213His) in the SULT1A1 gene.
|
21977969 |
2012 |
|
rs700518
|
|
|
0.030 |
GeneticVariation |
BEFREE |
A reduced risk of a breast cancer event for tamoxifen-treated patients with rs700518 variants was observed (BCFI CC/TC vs. TT: HR 0.53, 95 % CI 0.34-0.82, interaction P = 0.08), but not observed for letrozole-treated patients.
|
25935582 |
2015 |
|
rs10046
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A significant association was observed between the rs10046 polymorphism of the CYP19gene and breast cancer in Iranian patients.
|
27165202 |
2016 |
|
rs700519
|
|
|
0.070 |
GeneticVariation |
BEFREE |
A total of 22 studies with 10,592 cases and 11,720 controls were identified, and the results showed that R264C polymorphism was not associated with breast cancer risk in overall (T vs. C: OR = 1.061, 95% CI = 0.929-1.212) or race-based populations (T vs. C for Asian: OR = 1.169, 95% CI = 1.002-1.363; for Caucasian: OR = 0.787, 95% CI = 0.597-1.037); meanwhile, for Asian individuals, 3-bpDel/Ins polymorphism showed a significantly association with breast cancer susceptibility (for allele Del vs. allele Ins: OR = 1.278, 95% CI = 1.066-1.532) while the carriers of allele (TTTA)(12) can significantly decrease breast cancer risk (OR = 0.752, 95% CI = 0.603-0.939).
|
20052540 |
2010 |
|
rs2236722
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Aromatase and breast cancer: W39R, an inactive protein.
|
11916629 |
2002 |
|
rs1413421847
|
|
|
0.010 |
GeneticVariation |
BEFREE |
CYP17 (T34C), CYP19 (Trp39Arg), and FGFR2 (C906T) polymorphisms and the risk of breast cancer in south Indian women.
|
19469636 |
2009 |
|
rs2236722
|
|
|
0.040 |
GeneticVariation |
BEFREE |
CYP17 (T-34C) and CYP19 (Trp39Arg) polymorphisms and their cooperative effects on breast cancer susceptibility.
|
20133979 |
2010 |
|
rs2236722
|
|
|
0.040 |
GeneticVariation |
BEFREE |
CYP17 (T34C), CYP19 (Trp39Arg), and FGFR2 (C906T) polymorphisms and the risk of breast cancer in south Indian women.
|
19469636 |
2009 |
|
rs3751591
|
|
|
0.010 |
GeneticVariation |
BEFREE |
CYP19A1/rs3751591 was both associated with SHBG levels (P = 0.03) and with risk of BC (Incidence Rate Ratio = 2.12; 95 % Confidence Interval: 1.02-4.43) such that homozygous variant allele carriers had increased levels of serum SHBG and were at increased risk of BC.
|
27102200 |
2016 |
|
rs700518
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with body composition changes in women on aromatase inhibitors for ER (+) breast cancer.
|
26049585 |
2015 |
|
rs4646
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Genotyping for the CYP19 polymorphisms rs4646 (A/C), rs1065779 (A/C), CYP19 (TTTA)n (short allele/long (S/L) allele using the 7 TTTA repeat polymorphism as the cut-off), and rs1870050 (A/C) was performed on 296 patients with LN-negative, HR-positive breast cancers.
|
24324964 |
2013 |
|
rs1065779
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Genotyping for the CYP19 polymorphisms rs4646 (A/C), rs1065779 (A/C), CYP19 (TTTA)n (short allele/long (S/L) allele using the 7 TTTA repeat polymorphism as the cut-off), and rs1870050 (A/C) was performed on 296 patients with LN-negative, HR-positive breast cancers.
|
24324964 |
2013 |
|
rs10046
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Homozygotes of minor alleles of CYP19 rs10046 (CC) were associated with a reduced risk of BC with OR: 0.61 (95%CI = 0.39-0.95).
|
27323034 |
2016 |
|
rs10046
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In a case-control study nested within a breast self-examination trial conducted in China, we examined whether CYP19A1 polymorphisms (rs1870049, rs1004982, rs28566535, rs936306, rs11636639, rs767199, rs4775936, rs11575899, rs10046, and rs4646) were associated with risk of breast cancer and fibrocystic breast conditions.
|
19064562 |
2008 |
|
rs4646
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In a case-control study nested within a breast self-examination trial conducted in China, we examined whether CYP19A1 polymorphisms (rs1870049, rs1004982, rs28566535, rs936306, rs11636639, rs767199, rs4775936, rs11575899, rs10046, and rs4646) were associated with risk of breast cancer and fibrocystic breast conditions.
|
19064562 |
2008 |
|
rs700519
|
|
|
0.070 |
GeneticVariation |
BEFREE |
In addition, a stratified analysis by menopausal status indicated that the association of the CYP19 polymorphisms (rs10046 and rs700519) with BC risk was mainly evident in premenopausal women, and the association of CYP19 rs700519 with BC risk was significant in women less than 50 years old.
|
27323034 |
2016 |
|
rs10046
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In conclusion, breast cancer in Xinjiang Uigur women is closely connected with the age, BMI, parity, abortion, and CYP19 rs10046 polymorphisms.
|
26345775 |
2015 |
|
rs1008805
|
|
|
0.020 |
GeneticVariation |
BEFREE |
In conclusion, the homozygous minor allele (GG) of <i>CYP19A1</i> rs1008805 was identified to be significantly associated with an inferior clinical outcome of hormone therapy in postmenopausal hormone receptor-positive patients with early breast cancer.
|
29113261 |
2017 |
|
rs774053181
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In summary, the BRCA1 Cys39Gly</span> and CYP17A1 -34T>C genetic variations were associated with breast cancer risk.
|
29510000 |
2018 |
|
rs10046
|
|
|
0.100 |
GeneticVariation |
BEFREE |
No rs10046 genotypes were significantly associated with increased breast cancer risk or patient character</span>istics other than age at onset.
|
24402127 |
2014 |
|
rs700519
|
|
|
0.070 |
GeneticVariation |
BEFREE |
Our findings suggest that rs700519 and rs2069522 are associated with susceptibility to breast cancer among the Han Chinese population and have a cumulative effect with three other identified SNPs.
|
25689428 |
2015 |
|
rs1008805
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Our results suggest that premenopausal women carrying the G allele at CYP19 rs1008805 have increased risk of breast cancer.
|
17975727 |
2008 |
|
rs10046
|
|
|
0.100 |
GeneticVariation |
BEFREE |
SNPs rs10046 and rs4646 may influence the HER2 status of breast cancer tumors, and rs10046 genotypes are associated with an altered DFS.
|
18049890 |
2008 |